<unk> , sold under the brand name Scenesse, is a synthetic peptide and analogue of α-melanocyte stimulating hormone used to prevent skin damage from the sun in people with erythropoietic protoporphyria in the European Union since January 2015, and the United States since October 2019. As a medication it is administered in subcutaneous implant form; the implant lasts for two months. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Afamelanotide
Efgartigimod alfa
Astemizole
Crofelemer
Promazine
Tecovirimat
Viaspan
Retinol